We are developing KVD900 as an on-demand therapy for acute HAE attacks and are conducting a Phase 2 proof-of-concept study in HAE patients with enrollment complete. KVD824 is in development for prophylactic treatment of HAE with an expected IND filing in the first quarter of 2021. Our oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment of HAE for patients. In DME, an intravitreally administered plasma kallikrein inhibitor known as KVD001, completed a Phase 2 clinical trial in 2019.
We have an R&D team with an established track record in the pharmaceutical development of small molecule protease inhibitors, world-leading expertise in the role of plasma kallikrein in disease, and a management team with the capability to bring small molecules through the clinic to commercialization.
Our offices and labs are in Cambridge, MA and Salisbury, UK.